DAMIR HAMAMDZIC, DVM, PhD, (Veterinarian); ONE HEALTH NJ (Human, Animal, Plant) Steering Committee; Bio-Ethics; Animal Welfare and Regulatory Compliance (Janssen Pharmaceuticals); Seinfeld

Published: July 27, 2022, 8:55 p.m.

#veterinarian #bioethics #ONEHEALTH

\n

CONVERSATIONS WITH CALVIN WE THE SPECIES

\n

NEW: DAMIR HAMAMDZIC: DVM, PhD, (Veterinarian); ONE HEALTH NJ (Human, Animal, Plant) Steering Committee; Bio-Ethics; AND #Seinfeld

\n

\u201cA diverse, fascinating, timely, introspective & much anticipated interview. Not to be missed\u2026. you could listen to Damir all night\u2026.\u201d

\n

168 Interviews. GLOBAL Reach. Earth Life. Amazing People.

\n

PLEASE SUBSCRIBE (You can almost find any subject you want) https://www.youtube.com/c/ConversationswithCalvinWetheSpecIEs

\n

**

\n

DAMIR HAMAMDZIC, DVM, PhD, (Veterinarian); ONE HEALTH NJ (Human, Animal, Plant) Steering Committee; Bio-Ethics; Animal Welfare and Regulatory Compliance (Janssen Pharmaceuticals) Animal-Human Transplantation?; Seinfeld.(TV)

\n

YouTube:

\n

CONTACT: LinkedIn: https://www.linkedin.com/in/damir-hamamd%C5%BEi%C4%87-dvm-phd-cpia-1437b015/

\n

BIO: Dr. Damir Hamamdzic is a Scientist, veterinarian, & bioethicist. Currently he is Sr Scientist in charge of animal welfare & regulatory compliance at Johnson & Johnson. Previously, at Rutgers Office of Research Regulatory, also in charge of animal welfare, he established a post-approval monitoring program that encompasses all 4 Rutgers campuses, across 2 IACUCs, as well as oversight of NJIT\u2019s lab animal site. He utilized his scientific, scholarly, & quality assurance (QA) background to build lasting relationships with researchers & their staff. He also participated in teaching courses in Research Ethics for the grad students, as well as served as co-course director for \u201cAnimals and the Law\u201d course for the Rutgers Undergrad program.

\n

As a GCLP QA Mgr and a GCP Auditor, Dr. Hamamdzic supported U of Pennsylvania\u2019s Abramson Cancer Center in its corporate alliance with Novartis to develop novel breakthrough therapies for cancer. GCLP bridges gap between GLP & GCP regulations, an institutional risk in cellular & biologics-based therapies. He established a GCLP QA program & served as an auditor for the clinical GCP studies. As a Sr Research Investigator & an Assnt Director, he managed preclinical (GLP and GLP-like) large animal cardiology research studies as a part of the academic-industry alliance.

\n

As an Assistant Prof at Dept of Microbiology & Immunology at Medical Univ of So Carolina, Dr. Hamamdzic was a Principal Investigator & managed an active research program. He managed & mentored grad students, post-doctoral fellows & laboratory technicians. Hamamdzic's teaching responsibilities included teaching grad level courses to Ph.D. students & medical students. Based on his interest in ethics in research, data integrity, and reproducibility & because he thinks that education is an ongoing and never-ending process, he is currently pursuing a Masters in Bioethics degree at the U of Pennsylvania.

\n

**

\n

ALSO ON AUDIO: SPOTIFY http://spoti.fi/3bMYVYW

\n

GOOGLE PODCASTS http://bit.ly/38yH3yP

\n

edits by Claudine Smith- Email: casproductions01@gmail.com

\n

**

\n

PLEASE SUBSCRIBE(You can almost find any subject you want) #animalwelfare #animalrescue #rutgers #climatechange #womenshealth #ONEHEALTH #water #USC #singersongwriter #branding #nayarit #Mexico

\n

** ** ** ** **

\n

CLIMATE UPDATE:

\n

IT\u2019S N0W OR NEVER:

\n

Intergovernmental Panel on Climate Change (IPCC) released its second chapter on the impact of climate change. Many of the impacts of global warming are now simply "irreversible," the UN's latest assessment found.

\n

CLIMATE OPTIMISTS GROUP PANEL YOUTH and CLIMATE CHANGE and Beyond Sat June 4 2022

\n

YouTube: https://lnkd.in/eWN6QzKT